Relay Therapeutics (RLAY) Other Accumulated Expenses (2021 - 2026)

Relay Therapeutics (RLAY) has 6 years of Other Accumulated Expenses data on file, last reported at $847000.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $847000.0, down 49.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $847000.0 (down 49.64% YoY), and the FY2025 annual result was $463000.0, down 76.73% from the prior year.
• Other Accumulated Expenses grew to $847000.0 in Q1 2026 per RLAY's latest filing, from $463000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $26.9 million in Q3 2022 and troughed at $463000.0 in Q4 2025.
• A 5-year average of $8.8 million and a median of $1.7 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses soared 6504.04% in 2022, then slumped 96.96% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $26.2 million in 2022, then plunged by 95.4% to $1.2 million in 2023, then surged by 65.28% to $2.0 million in 2024, then tumbled by 76.73% to $463000.0 in 2025, then jumped by 82.94% to $847000.0 in 2026.
• Business Quant data shows RLAY's Other Accumulated Expenses at $847000.0 in Q1 2026, $463000.0 in Q4 2025, and $1.1 million in Q3 2025.